New drug combo aims to fight untreatable liver cancer

NCT ID NCT05557838

Ongoing Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 3 trial tests a combination of two immunotherapy drugs, durvalumab and tremelimumab, as the first treatment for people with advanced liver cancer that cannot be removed by surgery. The study involves 214 Chinese patients and will measure safety, side effects, and how well the drugs control the cancer. The goal is to see if this drug pair can offer a better option for patients who have not had prior systemic therapy.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: durvalumab and tremelimumab (immunotherapy drugs given by IV infusion)
What this could lead to: If successful, this combination could become a new first-line treatment option for Chinese patients with advanced liver cancer, potentially improving survival and tumor control.
What could go wrong: This is an open-label, single-country study with no placebo group, so results may be less definitive. Immunotherapy can cause serious immune-related side effects, and not all patients may respond.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATOCELLULAR CARCINOMA

Contacts and locations

Locations

Research Site

Beijing, 100021, China
Research Site

Beijing, 100142, China
Research Site

Beijing, 211405, China
Research Site

Beijing, CN-100730, China
Research Site

Changsha, 410005, China
Research Site

Changsha, 410013, China
Research Site

Chengdu, 610041, China
Research Site

Fuzhou, 350011, China
Research Site

Guangzhou, 510060, China
Research Site

Guangzhou, 510100, China
Research Site

Guangzhou, 510260, China
Research Site

Guangzhou, 510515, China
Research Site

Hangzhou, 310022, China
Research Site

Harbin, 150081, China
Research Site

Jinan, 2501117, China
Research Site

Nanjing, 2100008, China
Research Site

Nanjing, 210009, China
Research Site

Nanjing, 210029, China
Research Site

Ningbo, 315010, China
Research Site

Shanghai, 200032, China
Research Site

Shanghai, 200040, China
Research Site

Shenyang, 110001, China
Research Site

Tianjin, 300000, China
Research Site

Wenzhou, 325000, China
Research Site

Wuhan, 430022, China
Research Site

Wuhan, 430079, China
Research Site

Xi'an, 710038, China
Research Site

Zhangjiagang, 215699, China
Research Site

Zhengzhou, 450008, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.